A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, 4-PERIOD, CROSSOVER, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING ORAL DOSES OF PF-07328948 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS
Latest Information Update: 07 Nov 2024
At a glance
- Drugs PF 07328948 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Pfizer
Most Recent Events
- 05 Jun 2023 Status changed from active, no longer recruiting to completed.
- 28 Mar 2023 Planned End Date changed from 14 Apr 2023 to 3 May 2023.
- 28 Mar 2023 Planned primary completion date changed from 14 Apr 2023 to 3 May 2023.